
==== Front
Transl Cancer Res
Transl Cancer Res
TCR
Translational Cancer Research
2218-676X
2219-6803
AME Publishing Company

tcr-13-08-4507
10.21037/tcr-2024-2
Erratum
Erratum to erratum to miR-3614-3p suppresses cell aggressiveness of human breast cancer by targeting AKT3 and HDAC1 expression
Editorial Office
Translational Cancer Research
Correspondence to: Editorial Office. Translational Cancer Research. Email: tcr@amepc.org.
27 8 2024
31 8 2024
27 8 2024
13 8 45074509
20 11 2023
12 6 2024
2024 Translational Cancer Research. All rights reserved.
2024
Translational Cancer Research.
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.
==== Body
pmcIn the May 2023 issue of Translational Cancer Research, the paper titled “Erratum to miR-3614-3p suppresses cell aggressiveness of human breast cancer by targeting AKT3 and HDAC1 expression” (Transl Cancer Res 2023;12(5):1372-1375. doi: 10.21037/tcr-23-674) (1), was published for correction of Figure 1C and Figure 5C in the article (2) published earlier. However, there are still some errors found in the aforementioned Figures 1C,5C, as well as in Figure 4C, while the figure legends for Figures 1C,5C remain intact.

The Figure 1C should be corrected as:

Figure 1 Ectopic expression of miR-3614-3p ameliorates BC migration and invasion in vitro. (C) Transwell assays (magnification 200×) showed that miR-3614-3p depressed cell metastasis (stained in 0.1% crystal violet for 15 min; upper panel: migration assays; lower panel: invasion assays).

The Figure 4C and the legend should be corrected as:

Figure 4 AKT3 and HDAC1 are experimentally validated as direct targets of miR-3614-3p in human BC cells. (C) AKT3/HDAC1 mRNA and protein expressions were assessed in MCF-7 and MDA-MB-231 cells after transfection of miR-3614 expression vector/anti-miR-3614-3p.

The Figure 5C should be corrected as:

Figure 5 AKT3 and HDAC1 are the functional mediators downstream of miR-3614-3p in BC cells. (C) Transwell assays (magnification 200×) showed that si-AKT3/HDAC1 depressed cell metastasis (stained in 0.1% crystal violet for 15 min; upper panel: migration assays; lower panel: invasion assays).

The authors confirmed that these corrections do not change the description or original conclusions of the paper and sincerely apologize for any inconvenience caused by these mistakes.

Click here to view the updated version of the article.

Supplementary

The article’s supplementary files as

10.21037/tcr-2024-2
==== Refs
References

1 Editorial Office. Erratum to miR-3614-3p suppresses cell aggressiveness of human breast cancer by targeting AKT3 and HDAC1 expression. Transl Cancer Res 2023;12 :1372-5. 10.21037/tcr-23-674 37304547
2 Wang Z Jing X Li F miR-3614-3p suppresses cell aggressiveness of human breast cancer by targeting AKT3 and HDAC1 expression. Transl Cancer Res 2022;11 :1565-75. Erratum in: Transl Cancer Res 2023;12:1372-5. 10.21037/tcr-21-2419 35836520
